<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.1 20151215//EN" "https://jats.nlm.nih.gov/publishing/1.1/JATS-journalpublishing1.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="editorial" dtd-version="1.1" specific-use="sps-1.9" xml:lang="pt">
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Arq Bras Cardiol</journal-id>
      <journal-id journal-id-type="publisher-id">abc</journal-id>
      <journal-title-group>
        <journal-title>Arquivos Brasileiros de Cardiologia</journal-title>
        <abbrev-journal-title abbrev-type="publisher">Arq. Bras. Cardiol.</abbrev-journal-title>
      </journal-title-group>
      <issn pub-type="ppub">0066-782X</issn>
      <issn pub-type="epub">1678-4170</issn>
      <publisher>
        <publisher-name>Sociedade Brasileira de Cardiologia - SBC</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id specific-use="scielo-v3" pub-id-type="publisher-id">JWJjvybsNvgZVx4bjh7mbny</article-id>
      <article-id specific-use="scielo-v2" pub-id-type="publisher-id">S0066-782X2026000701002</article-id>
      <article-id pub-id-type="other">01002</article-id>
      <article-id pub-id-type="doi">10.36660/abc.20260506</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Minieditorial</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Al&#233;m da Complexidade da Les&#227;o: Precisamos de um Novo Escore Para Oclus&#245;es Coron&#225;rias Cr&#244;nicas?</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <contrib-id contrib-id-type="orcid">0000-0003-3511-7375</contrib-id>
          <name>
            <surname>Andrade</surname>
            <given-names>Pedro Beraldo de</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">
            <sup>1</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <contrib-id contrib-id-type="orcid">0000-0001-9075-9835</contrib-id>
          <name>
            <surname>Furquim</surname>
            <given-names>Thyago</given-names>
          </name>
          <xref ref-type="aff" rid="aff2">
            <sup>2</sup>
          </xref>
        </contrib>
      </contrib-group>
      <aff id="aff1">
        <label>1</label>
        <institution content-type="orgname">Santa Casa de Miseric&#243;rdia de Mar&#237;lia</institution>
        <addr-line>
          <named-content content-type="city">Marilia</named-content>
          <named-content content-type="state">SP</named-content>
        </addr-line>
        <country country="BR">Brasil</country>
        <institution content-type="original">Santa Casa de Miseric&#243;rdia de Mar&#237;lia, Marilia, SP &#8211; Brasil</institution>
      </aff>
      <aff id="aff2">
        <label>2</label>
        <institution content-type="orgname">UNICAMP</institution>
        <addr-line>
          <named-content content-type="city">Campinas</named-content>
          <named-content content-type="state">SP</named-content>
        </addr-line>
        <country country="BR">Brasil</country>
        <institution content-type="original">Universidade Estadual deCampinas (UNICAMP), Campinas, SP &#8211; Brasil</institution>
      </aff>
      <author-notes>
        <corresp id="c01"><label>Correspond&#234;ncia:</label> Pedro Beraldo de Andrade Santa Casa de Miseric&#243;rdia de Mar&#237;lia - Cardiologia Invasiva &#8211; Av. Vicente Ferreira, 828. CEP 17515-900, Mar&#237;lia, SP &#8211; Brasil E-mail: <email>pedroberaldo@gmail.com</email> </corresp>
      </author-notes>
      <pub-date date-type="pub" publication-format="electronic">
        <day>17</day>
        <month>08</month>
        <year>2026</year>
      </pub-date>
      <pub-date date-type="collection" publication-format="electronic">
        <year>2026</year>
      </pub-date>
      <volume>123</volume>
      <issue>7</issue>
      <elocation-id>e20260506</elocation-id>
      <history>
        <date date-type="received">
          <day>20</day>
          <month>06</month>
          <year>2026</year>
        </date>
        <date date-type="rev-recd">
          <day>24</day>
          <month>06</month>
          <year>2026</year>
        </date>
        <date date-type="accepted">
          <day>24</day>
          <month>06</month>
          <year>2026</year>
        </date>
      </history>
      <permissions>
        <license license-type="open-access" xlink:href="https://creativecommons.org/licenses/by/4.0/" xml:lang="pt">
          <license-p>Este &#233; um artigo de acesso aberto distribu&#237;do sob os termos da licen&#231;a de atribui&#231;&#227;o pelo Creative Commons</license-p>
        </license>
      </permissions>
      <kwd-group xml:lang="pt">
        <title>Palavras-chave:</title>
        <kwd>Oclus&#227;o coron&#225;ria</kwd>
        <kwd>Circula&#231;&#227;o colateral</kwd>
        <kwd>Inflama&#231;&#227;o</kwd>
      </kwd-group>
      <counts>
        <fig-count count="0"/>
        <table-count count="0"/>
        <equation-count count="0"/>
        <ref-count count="11"/>
      </counts>
    </article-meta>
  </front>
  <body>
    <p>O escore HALP (Hemoglobina, Albumina, Linf&#243;citos e Plaquetas) &#233; um &#237;ndice que combina par&#226;metros laboratoriais facilmente dispon&#237;veis e reflete o estado inflamat&#243;rio e nutricional de um indiv&#237;duo. Tradicionalmente utilizado em doen&#231;as oncol&#243;gicas<sup><xref ref-type="bibr" rid="B1">1</xref></sup> e inflamat&#243;rias,<sup><xref ref-type="bibr" rid="B2">2</xref></sup> recentemente emergiu como um marcador progn&#243;stico em diversas condi&#231;&#245;es cardiovasculares, incluindo s&#237;ndromes coron&#225;rias agudas,<sup><xref ref-type="bibr" rid="B3">3</xref></sup> insufici&#234;ncia card&#237;aca<sup><xref ref-type="bibr" rid="B4">4</xref></sup> e fibrila&#231;&#227;o atrial n&#227;o valvar.<sup><xref ref-type="bibr" rid="B5">5</xref></sup> Valores de HALP mais baixos t&#234;m sido associados a um estado pr&#243;-inflamat&#243;rio, homeostase hematol&#243;gica prejudicada e pior estado nutricional.</p>
    <p>Esses fatores podem afetar negativamente os processos de remodela&#231;&#227;o vascular, levando &#224; angiog&#234;nese patol&#243;gica.<sup><xref ref-type="bibr" rid="B6">6</xref></sup> Nesse contexto, Akkaya e &#214;zt&#252;rk analisaram retrospectivamente 269 pacientes com oclus&#245;es coron&#225;rias cr&#244;nicas identificada por angiografia coron&#225;ria e demonstraram que o escore HALP apresentou excelente desempenho discriminat&#243;rio para a detec&#231;&#227;o de circula&#231;&#227;o colateral bem desenvolvida.<sup><xref ref-type="bibr" rid="B7">7</xref></sup> Conforme relatado nesta edi&#231;&#227;o dos Arquivos Brasileiros de Cardiologia, o escore HALP foi significativamente maior em pacientes com circula&#231;&#227;o colateral proeminente em compara&#231;&#227;o com aqueles com colaterais pouco desenvolvidas (75,5 &#177; 13,9 vs. 35,1 &#177; 11,3; p &lt; 0,001) e foi um preditor independente desse achado angiogr&#225;fico (OR: 0,88; IC 95%: 0,83&#8211;0,93; p &lt; 0,001). A an&#225;lise da curva ROC (<italic>Receiver Operating Characteristic</italic>) demonstrou uma AUC de 0,958 (IC 95%: 0,93&#8211;0,98), com um valor de corte &gt;49,08, resultando em uma sensibilidade de 91,3% e uma especificidade de 90,8%. Em um estudo semelhante, S&#252;leymano&#287;lu et al. avaliaram retrospectivamente 240 pacientes com oclus&#227;o coron&#225;ria cr&#244;nica e confirmaram que o escore HALP estava positivamente associado &#224; qualidade da circula&#231;&#227;o colateral, avaliada pela classifica&#231;&#227;o de Werner, permanecendo um forte preditor independente na an&#225;lise multivari&#225;vel.<sup><xref ref-type="bibr" rid="B8">8</xref></sup></p>
    <p>A indica&#231;&#227;o mais robusta para o tratamento de oclus&#245;es coron&#225;rias cr&#244;nicas continua sendo o al&#237;vio dos sintomas de angina.<sup><xref ref-type="bibr" rid="B9">9</xref></sup> Uma vez selecionada a interven&#231;&#227;o coron&#225;ria percut&#226;nea, o planejamento do procedimento se baseia principalmente na angiografia invasiva, cada vez mais complementada pela angiotomografia coron&#225;ria, que permite a identifica&#231;&#227;o de canais colaterais intervencion&#225;veis. Diversos sistemas de escore angiogr&#225;fico, incluindo J-CTO (<italic>Multicenter CTO Registry in Japan</italic>), PROGRESS-CTO (<italic>Prospective Global Registry of Chronic Total Occlusion Interventions</italic>), CASTLE [idade na cirurgia de revasculariza&#231;&#227;o do mioc&#225;rdio (&#8805;70 anos), anatomia do coto (obtuso ou invis&#237;vel), grau de tortuosidade (grave ou n&#227;o vis&#237;vel), comprimento da oclus&#227;o (&#8805;20 mm) e extens&#227;o da calcifica&#231;&#227;o (grave)] e CT-RECTOR (<italic>Computed Tomography Registry of Chronic Total Occlusion Revascularization</italic>), auxiliam na predi&#231;&#227;o do sucesso t&#233;cnico.<sup><xref ref-type="bibr" rid="B10">10</xref></sup> Nesse contexto, precisamos de um novo escore capaz de predizer a probabilidade de identificar canais colaterais adequados para interven&#231;&#227;o, a fim de sistematizar ainda mais o manejo de pacientes com oclus&#245;es coron&#225;rias cr&#244;nicas? A resposta provavelmente &#233; n&#227;o, visto que a avalia&#231;&#227;o anat&#244;mica por meio de angiografia invasiva ou tomografia computadorizada coron&#225;ria &#233; invariavelmente necess&#225;ria, e tal escore dificilmente influenciaria substancialmente esse processo de tomada de decis&#227;o.</p>
    <p>Poderia o escore HALP agregar valor cl&#237;nico progn&#243;stico &#224; tomada de decis&#227;o quanto &#224; indica&#231;&#227;o ou n&#227;o de revasculariza&#231;&#227;o mioc&#225;rdica em pacientes com oclus&#227;o coron&#225;ria cr&#244;nica? Trata-se de um conceito potencialmente relevante a ser explorado, uma vez que a qualidade da circula&#231;&#227;o colateral estaria relacionada a menor extens&#227;o de isquemia, melhor preserva&#231;&#227;o da fun&#231;&#227;o ventricular esquerda, menor remodelamento ventricular e maior viabilidade mioc&#225;rdica.<sup><xref ref-type="bibr" rid="B11">11</xref></sup> Linhas de pesquisa futuras poderiam investigar o poder preditivo do escore HALP para identificar pacientes que se beneficiariam da estrat&#233;gia de revasculariza&#231;&#227;o, para al&#233;m da melhora de sintomatologia, comparando o progn&#243;stico de pacientes submetidos a tratamento bem-sucedido de acordo com a categoria de escore HALP alto ou baixo, acrescentando, assim, uma ferramenta adicional &#224; dif&#237;cil tomada de decis&#227;o na condu&#231;&#227;o de pacientes portadores de oclus&#245;es coron&#225;rias cr&#244;nicas.</p>
  </body>
  <back>
    <ref-list>
      <title>Refer&#234;ncias</title>
      <ref id="B1">
        <label>1</label>
        <mixed-citation>1. Demir N, G&#246;kmen I, Karateke YS, Ilhan A, Yildiz F, Garbioglu DB, et al. HALP Score as a Prognostic Marker for Overall Survival in Advanced Pancreatic Cancer. Front Oncol. 2025;15:1542463. doi: 10.3389/fonc.2025.1542463.</mixed-citation>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Demir</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>G&#246;kmen</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Karateke</surname>
              <given-names>YS</given-names>
            </name>
            <name>
              <surname>Ilhan</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Yildiz</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Garbioglu</surname>
              <given-names>DB</given-names>
            </name>
            <etal>et al</etal>
          </person-group>
          <article-title>HALP Score as a Prognostic Marker for Overall Survival in Advanced Pancreatic Cancer</article-title>
          <source>Front Oncol</source>
          <year>2025</year>
          <volume>15</volume>
          <size units="pages">1542463</size>
          <pub-id pub-id-type="doi">10.3389/fonc.2025.1542463</pub-id>
        </element-citation>
      </ref>
      <ref id="B2">
        <label>2</label>
        <mixed-citation>2. &#199;elik G, &#199;ilingiroglu &#199;, Ugur S, Kizil SD. Clinical Relevance of the HALP Score in Rheumatoid Arthritis: Association with Disease Activity and Inflammatory Burden. Arch Rheumatol. 2026;41(2):134-43. doi: 10.5152/ArchRheumatol.2026.25181.</mixed-citation>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>&#199;elik</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>&#199;ilingiroglu</surname>
              <given-names>&#199;</given-names>
            </name>
            <name>
              <surname>Ugur</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Kizil</surname>
              <given-names>SD</given-names>
            </name>
          </person-group>
          <article-title>Clinical Relevance of the HALP Score in Rheumatoid Arthritis: Association with Disease Activity and Inflammatory Burden</article-title>
          <source>Arch Rheumatol</source>
          <year>2026</year>
          <volume>41</volume>
          <issue>2</issue>
          <fpage>134</fpage>
          <lpage>143</lpage>
          <pub-id pub-id-type="doi">10.5152/ArchRheumatol.2026.25181</pub-id>
        </element-citation>
      </ref>
      <ref id="B3">
        <label>3</label>
        <mixed-citation>3. Karakayali M, Omar T, Artac I, Ilis D, Arslan A, Altunova M, et al. The Prognostic Value of HALP Score in Predicting in-Hospital Mortality in Patients with ST-Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention. Coron Artery Dis. 2023;34(7):483-8. doi: 10.1097/MCA.0000000000001271.</mixed-citation>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Karakayali</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Omar</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Artac</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Ilis</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Arslan</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Altunova</surname>
              <given-names>M</given-names>
            </name>
            <etal>et al</etal>
          </person-group>
          <article-title>The Prognostic Value of HALP Score in Predicting in-Hospital Mortality in Patients with ST-Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention</article-title>
          <source>Coron Artery Dis</source>
          <year>2023</year>
          <volume>34</volume>
          <issue>7</issue>
          <fpage>483</fpage>
          <lpage>488</lpage>
          <pub-id pub-id-type="doi">10.1097/MCA.0000000000001271</pub-id>
        </element-citation>
      </ref>
      <ref id="B4">
        <label>4</label>
        <mixed-citation>4. Liu L, Gong B, Wang W, Xu K, Wang K, Song G. Association between Haemoglobin, Albumin, Lymphocytes, and Platelets and Mortality in Patients with Heart Failure. ESC Heart Fail. 2024;11(2):1051-60. doi: 10.1002/ehf2.14662.</mixed-citation>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Liu</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Gong</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Wang</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Xu</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Wang</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Song</surname>
              <given-names>G</given-names>
            </name>
          </person-group>
          <article-title>Association between Haemoglobin, Albumin, Lymphocytes, and Platelets and Mortality in Patients with Heart Failure</article-title>
          <source>ESC Heart Fail</source>
          <year>2024</year>
          <volume>11</volume>
          <issue>2</issue>
          <fpage>1051</fpage>
          <lpage>1060</lpage>
          <pub-id pub-id-type="doi">10.1002/ehf2.14662</pub-id>
        </element-citation>
      </ref>
      <ref id="B5">
        <label>5</label>
        <mixed-citation>5. S&#246;ner S, G&#252;zel T, Aktan A, Kili&#231; R, S&#246;ner HT, Demir M, et al. Prognostic Value of Hemoglobin, Albumin, Lymphocyte, Platelet (HALP) Scores in Patients with Non-Valvular Atrial Fibrillation: Insights from the AFTER-2 Study. BMC Cardiovasc Disord. 2025;25(1):528. doi: 10.1186/s12872-025-04993-1.</mixed-citation>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>S&#246;ner</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>G&#252;zel</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Aktan</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Kili&#231;</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>S&#246;ner</surname>
              <given-names>HT</given-names>
            </name>
            <name>
              <surname>Demir</surname>
              <given-names>M</given-names>
            </name>
            <etal>et al</etal>
          </person-group>
          <article-title>Prognostic Value of Hemoglobin, Albumin, Lymphocyte, Platelet (HALP) Scores in Patients with Non-Valvular Atrial Fibrillation: Insights from the AFTER-2 Study</article-title>
          <source>BMC Cardiovasc Disord</source>
          <year>2025</year>
          <volume>25</volume>
          <issue>1</issue>
          <size units="pages">528</size>
          <pub-id pub-id-type="doi">10.1186/s12872-025-04993-1</pub-id>
        </element-citation>
      </ref>
      <ref id="B6">
        <label>6</label>
        <mixed-citation>6. Dudley AC, Griffioen AW. Pathological Angiogenesis: Mechanisms and Therapeutic Strategies. Angiogenesis. 2023;26(3):313-47. doi: 10.1007/s10456-023-09876-7.</mixed-citation>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Dudley</surname>
              <given-names>AC</given-names>
            </name>
            <name>
              <surname>Griffioen</surname>
              <given-names>AW</given-names>
            </name>
          </person-group>
          <article-title>Pathological Angiogenesis: Mechanisms and Therapeutic Strategies</article-title>
          <source>Angiogenesis</source>
          <year>2023</year>
          <volume>26</volume>
          <issue>3</issue>
          <fpage>313</fpage>
          <lpage>347</lpage>
          <pub-id pub-id-type="doi">10.1007/s10456-023-09876-7</pub-id>
        </element-citation>
      </ref>
      <ref id="B7">
        <label>7</label>
        <mixed-citation>7. Akkaya H, &#214;zt&#252;rk M. O Escore HALP como um Novo Marcador Associado &#224; Circula&#231;&#227;o Colateral Coronariana em Pacientes com Oclus&#227;o Total Cr&#244;nica. Arq Bras Cardiol; 123(7):e20260206.doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.36660/abc.20260206">https://doi.org/10.36660/abc.20260206</ext-link>.</mixed-citation>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Akkaya</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>&#214;zt&#252;rk</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>O Escore HALP como um Novo Marcador Associado &#224; Circula&#231;&#227;o Colateral Coronariana em Pacientes com Oclus&#227;o Total Cr&#244;nica</article-title>
          <source>Arq Bras Cardiol</source>
          <volume>123</volume>
          <issue>7</issue>
          <elocation-id>e20260206</elocation-id>
          <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.36660/abc.20260206">https://doi.org/10.36660/abc.20260206</ext-link>
        </element-citation>
      </ref>
      <ref id="B8">
        <label>8</label>
        <mixed-citation>8. S&#252;leymanoglu C, Polat F, Pa&#231;aci E, Terzi S. The HALP Score and Its Association with Coronary Collateral Circulation Development in Chronic Total Occlusion Patients. Catheter Cardiovasc Interv. 2026;107(7):2261-74. doi: 10.1002/ccd.70613.</mixed-citation>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>S&#252;leymanoglu</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Polat</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Pa&#231;aci</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Terzi</surname>
              <given-names>S</given-names>
            </name>
          </person-group>
          <article-title>The HALP Score and Its Association with Coronary Collateral Circulation Development in Chronic Total Occlusion Patients</article-title>
          <source>Catheter Cardiovasc Interv</source>
          <year>2026</year>
          <volume>107</volume>
          <issue>7</issue>
          <fpage>2261</fpage>
          <lpage>2274</lpage>
          <pub-id pub-id-type="doi">10.1002/ccd.70613</pub-id>
        </element-citation>
      </ref>
      <ref id="B9">
        <label>9</label>
        <mixed-citation>9. Brilakis ES, Mashayekhi K, Tsuchikane E, Abi Rafeh N, Alaswad K, Araya M, et al. Guiding Principles for Chronic Total Occlusion Percutaneous Coronary Intervention. Circulation. 2019;140(5):420-33. doi: 10.1161/CIRCULATIONAHA.119.039797.</mixed-citation>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Brilakis</surname>
              <given-names>ES</given-names>
            </name>
            <name>
              <surname>Mashayekhi</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Tsuchikane</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Abi Rafeh</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Alaswad</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Araya</surname>
              <given-names>M</given-names>
            </name>
            <etal>et al</etal>
          </person-group>
          <article-title>Guiding Principles for Chronic Total Occlusion Percutaneous Coronary Intervention</article-title>
          <source>Circulation</source>
          <year>2019</year>
          <volume>140</volume>
          <issue>5</issue>
          <fpage>420</fpage>
          <lpage>433</lpage>
          <pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.119.039797</pub-id>
        </element-citation>
      </ref>
      <ref id="B10">
        <label>10</label>
        <mixed-citation>10. Brilakis ES, Sandoval Y, Azzalini L, Leibundgut G, Garbo R, Hall AB, et al. Chronic Total Occlusion Percutaneous Coronary Intervention: Present and Future. Circ Cardiovasc Interv. 2025;18(6):e014801. doi: 10.1161/CIRCINTERVENTIONS.124.014801.</mixed-citation>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Brilakis</surname>
              <given-names>ES</given-names>
            </name>
            <name>
              <surname>Sandoval</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Azzalini</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Leibundgut</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Garbo</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Hall</surname>
              <given-names>AB</given-names>
            </name>
            <etal>et al</etal>
          </person-group>
          <article-title>Chronic Total Occlusion Percutaneous Coronary Intervention: Present and Future</article-title>
          <source>Circ Cardiovasc Interv</source>
          <year>2025</year>
          <volume>18</volume>
          <issue>6</issue>
          <elocation-id>e014801</elocation-id>
          <pub-id pub-id-type="doi">10.1161/CIRCINTERVENTIONS.124.014801</pub-id>
        </element-citation>
      </ref>
      <ref id="B11">
        <label>11</label>
        <mixed-citation>11. Schumacher SP, Everaars H, Stuijfzand WJ, Huynh JW, van Diemen PA, Bom MJ, et al. Coronary Collaterals and Myocardial Viability in Patients with Chronic Total Occlusions. EuroIntervention. 2020;16(6):e453-61. doi: 10.4244/EIJ-D-19-01006.</mixed-citation>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Schumacher</surname>
              <given-names>SP</given-names>
            </name>
            <name>
              <surname>Everaars</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Stuijfzand</surname>
              <given-names>WJ</given-names>
            </name>
            <name>
              <surname>Huynh</surname>
              <given-names>JW</given-names>
            </name>
            <name>
              <surname>van Diemen</surname>
              <given-names>PA</given-names>
            </name>
            <name>
              <surname>Bom</surname>
              <given-names>MJ</given-names>
            </name>
            <etal>et al</etal>
          </person-group>
          <article-title>Coronary Collaterals and Myocardial Viability in Patients with Chronic Total Occlusions</article-title>
          <source>EuroIntervention</source>
          <year>2020</year>
          <volume>16</volume>
          <issue>6</issue>
          <fpage>e453</fpage>
          <lpage>e461</lpage>
          <pub-id pub-id-type="doi">10.4244/EIJ-D-19-01006</pub-id>
        </element-citation>
      </ref>
    </ref-list>
    <fn-group>
      <fn fn-type="other">
        <label>Minieditorial referente ao artigo:</label>
        <p> O Escore HALP como um Novo Marcador Associado &#224; Circula&#231;&#227;o Colateral Coronariana em Pacientes com Oclus&#227;o Total Cr&#244;nica</p>
      </fn>
    </fn-group>
  </back>
  <sub-article article-type="translation" id="TRen" xml:lang="en">
    <front-stub>
      <article-id pub-id-type="doi">10.36660/abc.20260506i</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Short Editorial</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Beyond Lesion Complexity: Do We Need a New Score for Chronic Total Occlusions?</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <contrib-id contrib-id-type="orcid">0000-0003-3511-7375</contrib-id>
          <name>
            <surname>Andrade</surname>
            <given-names>Pedro Beraldo de</given-names>
          </name>
          <xref ref-type="aff" rid="aff1001">
            <sup>1</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <contrib-id contrib-id-type="orcid">0000-0001-9075-9835</contrib-id>
          <name>
            <surname>Furquim</surname>
            <given-names>Thyago</given-names>
          </name>
          <xref ref-type="aff" rid="aff2001">
            <sup>2</sup>
          </xref>
        </contrib>
      </contrib-group>
      <aff id="aff1001">
        <label>1</label>
        <country country="BR">Brazil</country>
        <institution content-type="original">Santa Casa de Miseric&#243;rdia de Mar&#237;lia, Marilia, SP &#8211; Brazil</institution>
      </aff>
      <aff id="aff2001">
        <label>2</label>
        <country country="BR">Brazil</country>
        <institution content-type="original">Universidade Estadual de Campinas (UNICAMP), Campinas, SP &#8211; Brazil</institution>
      </aff>
      <author-notes>
        <corresp id="c01001"><label>Mailing Address:</label> Pedro Beraldo de Andrade Santa Casa de Miseric&#243;rdia de Mar&#237;lia - Cardiologia Invasiva &#8211; Av. Vicente Ferreira, 828. Postal Code 17515-900, Mar&#237;lia, SP &#8211; Brasil E-mail: pedroberaldo@gmail.com </corresp>
      </author-notes>
      <kwd-group xml:lang="en">
        <title>Keywords:</title>
        <kwd>Coronary Occlusion</kwd>
        <kwd>Collateral Circulation</kwd>
        <kwd>Inflammation</kwd>
      </kwd-group>
    </front-stub>
    <body>
      <p>The Hemoglobin, Albumin, Lymphocyte, and Platelet (HALP) score is an index that combines readily available laboratory parameters and reflects an individual&#8217;s inflammatory and nutritional status. Traditionally used in oncologic<sup><xref ref-type="bibr" rid="B1">1</xref></sup> and inflammatory diseases,<sup><xref ref-type="bibr" rid="B2">2</xref></sup> it has recently emerged as a prognostic marker in various cardiovascular conditions, including acute coronary syndromes,<sup><xref ref-type="bibr" rid="B3">3</xref></sup> heart failure,<sup><xref ref-type="bibr" rid="B4">4</xref></sup> and non-valvular atrial fibrillation.<sup><xref ref-type="bibr" rid="B5">5</xref></sup> Lower HALP values have been associated with a pro-inflammatory state, impaired hematologic homeostasis, and poorer nutritional status.</p>
      <p>These factors may adversely affect vascular remodeling processes, leading to pathological angiogenesis.<sup><xref ref-type="bibr" rid="B6">6</xref></sup> In this context, Akkaya and &#214;zt&#252;rk retrospectively analyzed 269 patients with chronic total coronary occlusion identified by coronary angiography and demonstrated that the HALP score exhibited excellent discriminatory performance for the detection of well-developed collateral circulation.<sup><xref ref-type="bibr" rid="B7">7</xref></sup> As reported in the current issue of the <italic>Arquivos Brasileiros de Cardiologia</italic>, the HALP score was significantly higher in patients with prominent collateral circulation compared with those with poorly developed collaterals (75.5 &#177; 13.9 vs. 35.1 &#177; 11.3; p &lt; 0.001), and was an independent predictor of this angiographic finding (OR: 0.88; 95% CI: 0.83&#8211;0.93; p &lt; 0.001). Receiver operating characteristic (ROC) curve analysis demonstrated an AUC of 0.958 (95% CI: 0.93&#8211;0.98), with a cutoff value &gt;49.08, yielding a sensitivity of 91.3% and a specificity of 90.8%. In a similar study, S&#252;leymano&#287;lu et al. retrospectively evaluated 240 patients with chronic total coronary occlusion and confirmed that the HALP score was positively associated with collateral circulation quality, as assessed by the Werner classification, remaining a strong independent predictor in multivariable analysis.<sup><xref ref-type="bibr" rid="B8">8</xref></sup></p>
      <p>The most robust indication for the treatment of chronic total coronary occlusions remains the relief of anginal symptoms.<sup><xref ref-type="bibr" rid="B9">9</xref></sup> Once percutaneous coronary intervention is selected, procedural planning is based primarily on invasive angiography, increasingly complemented by coronary computed tomography angiography, which allows identification of interventional collateral channels. Several angiographic scoring systems, including J-CTO (Multicenter CTO Registry in Japan), PROGRESS-CTO (Prospective Global Registry of Chronic Total Occlusion Interventions), CASTLE [CABG age (&#8805;70 years), stump anatomy (blunt or invisible), tortuosity degree (severe or unseen), length of occlusion (&#8805;20 mm), and extent of calcification (severe)], and CT-RECTOR (Computed Tomography Registry of Chronic Total Occlusion Revascularization), assist in predicting technical success.<sup><xref ref-type="bibr" rid="B10">10</xref></sup> In this context, do we need a new score capable of predicting the likelihood of identifying collateral channels suitable for intervention in order to further systematize the management of patients with chronic total coronary occlusions? The answer is probably no, since anatomical assessment through invasive angiography or coronary computed tomography is invariably required, and such a score would be unlikely to substantially influence this decision-making process.</p>
      <p>Could the HALP score provide additional prognostic value in guiding revascularization decisions for patients with chronic total coronary occlusions? This is a potentially relevant concept worthy of further investigation, as the quality of collateral circulation has been associated with lower ischemic burden, better preservation of left ventricular function, reduced ventricular remodeling, and greater myocardial viability.<sup><xref ref-type="bibr" rid="B1">1</xref><xref ref-type="bibr" rid="B1">1</xref></sup> Future studies could evaluate the predictive value of the HALP score for identifying patients most likely to benefit from a revascularization strategy beyond symptomatic improvement. Comparing outcomes among patients undergoing successful chronic total occlusion recanalization between high- and low-HALP score categories could provide important insights into HALP&#8217;s potential role in patient selection, ultimately adding another tool to support decision-making for one of the most challenging aspects of managing chronic total coronary occlusions.</p>
    </body>
    <back>
      <fn-group>
        <fn fn-type="other">
          <label>Short Editorial related to the article:</label>
          <p> HALP Score as a Novel Marker Associated with Coronary Collateral Circulation in Patients with Chronic Total Occlusion</p>
        </fn>
      </fn-group>
    </back>
  </sub-article>
</article>
